What Spasmoctyl Treats: Main Uses and Benefits

This medication is commonly used to help with symptomatic relief for the painful, involuntary muscle contractions, or spasms, that occur in the digestive tract. It is considered relevant for the treatment of spasmodic pain of the intestines.

It is relevant when supportive symptom management is appropriate, targeting symptom clusters such as abdominal cramping, generalized gut discomfort, and associated bloating. Spasmoctyl is commonly used to help with conditions characterized by periods of heightened symptoms, including Irritable Bowel Syndrome (IBS). It may assist with managing these symptoms that interfere with daily comfort.

“This approach provides support that helps ease the overall symptom burden of persistent symptoms.”

This contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability when manifestations are more noticeable.

---

Quick Fact: Support for Symptoms of Abdominal Spasms

Regulatory References

1. Malta Medicines Authority

The official regulatory profile for Spasmoctyl (Otilonium Bromide) defines patient eligibility based on age, physiological status, and pre-existing conditions. The medicine is primarily intended for Adults (18 years and older). Use is not recommended for the pediatric population (patients below 18 years) because its safety and efficacy in this age group have not been formally established.

Absolute Contraindications (Must Not Use)

Spasmoctyl is contraindicated and must not be used by patients with a known hypersensitivity to Otilonium Bromide or its components. It is also contraindicated for individuals with specific hereditary metabolic disorders, such as total lactase deficiency or galactose intolerance, due to the drug's excipient content.

Restricted and Conditional Use

Use requires caution in subjects with glaucoma, prostatic hypertrophy (enlarged prostate), or pyloric stenosis. Regarding reproductive status, use is preferable to avoid during both pregnancy and breastfeeding as a precautionary measure, and is only to be administered under medical supervision if absolutely necessary. Furthermore, specific clinical studies on use in patients with renal or hepatic impairment have not been established.

Interactions with other medicines and products

The official regulatory profile for Spasmoctyl (Otilonium Bromide) is characterized by a minimal likelihood of systemic interactions. This is consistent with the medicine's highly localized action within the gastrointestinal tract and its negligible absorption into the bloodstream.

---

Official Regulatory Status of Interaction Studies

Category	Regulatory Statement
Documented Interaction Studies	No formal interaction studies of otilonium bromide with other medicinal products were performed.
Relevance to Co-administration	The medicine’s effect on gastrointestinal transit time is not considered relevant for the absorption of other orally taken concomitant medicinal products.

---

Interaction Profile Summary

Contraindicated Combinations and Restrictions: No specific medicinal products are formally listed in official regulatory documents as prohibited for co-administration due to an interaction risk. Consequently, there are no specific interaction-related restrictions documented.

Metabolic and Pharmacodynamic Interactions: Due to the absence of formal studies, regulatory information lists no specific pharmacokinetic (CYP-mediated) or pharmacodynamic interactions for otilonium bromide.

Timing and Concomitant Products: No mandatory timing separation rules, or special requirements for co-administration with other medicines, food, alcohol, or supplements are documented in official prescribing information.

The structure of the regulatory data reflects a status where no clinically significant systemic interaction risks have been formally identified or documented in the official prescribing information.

The mechanism of Otilonium Bromide is a multi-modal pharmacodynamic action directed at the smooth muscle and neural pathways of the intestinal wall.

Direct Regulation of Intestinal Smooth Muscle Contractility

The primary action is focused directly on the smooth muscle cell membrane, where the molecule acts as a non-competitive blocker of voltage-gated calcium channels ( Ca V), targeting the L-type and T-type subtypes. By inhibiting the influx of calcium ions ( Ca^2+), the molecule prevents the critical rise in intracellular calcium needed to sustain muscle contraction. This action directly leads to the physiological consequence of smooth muscle relaxation (spasmolysis), contributing to the reduction of abnormal contractility patterns.

Modulation of Excitatory Neural Signaling

A secondary mechanistic domain involves the attenuation of neural signals that mediate excessive gut motility and sensory input. The drug acts as an antagonist on Muscarinic M3 Receptors, reducing the excitatory effect of acetylcholine. Concurrently, it interacts with Tachykinin Neurokinin-2 ( NK2) Receptors, a pathway involved in promoting motility and afferent neuron sensitization. This dual modulation affects the signaling pathways that contribute to muscle hyperactivity and afferent neuron sensitization.

Mechanistic Constraint and Localized Action

The molecule’s quaternary ammonium structure is a key determinant of its action, as it limits systemic absorption. This structural constraint results in the multi-target mechanism—on Ca^2+ channels, M3, and NK2 receptors—being localized and peripheral. This constraint means the molecule's mechanistic effects are largely confined to the gastrointestinal tract.

How to Use Spasmoctyl (Official Dosing Instructions)

This section outlines the general principles for the administration of Spasmoctyl (Otilonium Bromide), focusing strictly on dosage and use patterns.

---

Administration and Dosage

The method of use for this medicine is by oral administration. The product is supplied as a 40 mg film-coated tablet, which defines the standard unit of the dose.

Usage Parameter	Official Instruction (Adults/Elderly)
Single Dose	One 40 mg tablet
Daily Frequency	2 to 3 times daily
Total Daily Dose	80 mg to 120 mg

---

Procedural Instructions and Timing

To ensure proper use, specific conditions for intake must be followed:

• Intake Method: Tablets must be swallowed whole with a glass of water. They should not be broken, crushed, or chewed.
• Timing: Administration is directed to take place preferably 20 minutes before a meal.
• Treatment Duration: There is generally no set limitation on the duration of treatment, as this depends on the clinical condition. However, the need for continued use may be periodically re-assessed. If symptoms persist beyond 14 days, a review of the diagnosis is typically recommended.

---

Use in Specific Populations

• Older Adults (Elderly): The standard adult dosing regimen is applicable for this population.
• Children and Adolescents: The 40 mg tablets are not recommended for use in children and adolescents below 18 years old, as the safety and efficacy profiles have not been established in this age group.

Note on Missed Dose: If a dose is missed, a double dose must not be taken; the usual dosing schedule should be resumed with the next scheduled tablet.

Spasmoctyl: Recent Clinical Evidence

Spasmoctyl (active ingredient otilonium bromide) is classified as an intestinal antispasmodic primarily evaluated for the symptomatic management of Irritable Bowel Syndrome (IBS) and painful spastic conditions of the distal enteric tract.

Clinical Trial Findings

Research has explored the effects of otilonium bromide on key symptoms of functional gastrointestinal disorders. The body of evidence includes randomized controlled trials (RCTs) and subsequent meta-analyses comparing the drug to placebo.

Symptom Evaluated	Key Findings from Studies	Research Focus
Abdominal Pain	Studies showed improvement in the frequency and intensity of abdominal pain compared to placebo.	Pain severity and frequency.
Abdominal Bloating/Distension	Research observed a reduction in the severity of abdominal distension.	Discomfort and patient well-being.
Global Symptom Relief	Some studies reported that participants experienced overall improvement in symptoms when compared to placebo.	Composite endpoint of IBS symptoms.

Comparison and Long-Term Use

Otilonium bromide has been included in meta-analyses with other antispasmodic agents, with some research suggesting a favorable profile in terms of efficacy metrics (e.g., number needed to treat, or NNT) for global symptom relief in IBS patients compared to placebo. Findings also suggest that the benefit of using the drug may be maintained over extended periods, with some research evaluating effects over 10 to 15 weeks.

Safety and Tolerability

Due to its poor systemic absorption, the drug is primarily designed to act locally on the smooth muscle of the colon and rectum. Clinical studies have explored its tolerability, reporting that it is generally well tolerated, with a low incidence of typical systemic side effects associated with other types of antispasmodics.

Key Studies & References

1. World Gastroenterology Organisation (WGO) Global Guideline: Irritable Bowel Syndrome (IBS)

How to Store and Dispose of Spasmoctyl?

This section outlines the mandatory storage and disposal rules for Spasmoctyl (Otilonium Bromide) based on official regulatory documentation.

---

Mandatory Storage Conditions

Spasmoctyl must be stored below 30 C (86 F) and requires protection from both heat and moisture. To maintain its quality, the medication must remain in its original package.

---

Child Safety and Stability

It is required to keep this medicine out of the sight and reach of children. The product must not be used after the expiry date (EXP) stated on the carton and blister packaging.

---

Official Disposal Instructions

Unused or expired Spasmoctyl must not be thrown away via wastewater or household waste. For correct pharmaceutical waste handling, users must consult a pharmacist for guidance on how to properly discard the unused medicine to help protect the environment.